"10.1371_journal.pone.0092750","plos one","2014-03-26T00:00:00Z","Jun Wang; David Land; Kenjiro Ono; Jorge Galvez; Wei Zhao; Prashant Vempati; John W Steele; Alice Cheng; Masahito Yamada; Samara Levine; Paolo Mazzola; Giulio M Pasinetti","Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America; Medisyn Technologies, Inc. Minnetonka, Minnesota, United States of America; Department of Neurology and Neurobiology of Aging, Kanazawa University, Kanazawa, Japan; Molecular Topology & Drug Design Unit, University of Valencia, Valencia, Spain; Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York New York, United States of America","Conceived and designed the experiments: JW DL MY GMP. Performed the experiments: JW KO JG WZ PV JS AC PM. Analyzed the data: JW JG DL SL GMP. Wrote the paper: JW SL GMP.","We have read the journals policy and have the following conflicts: David Land is affiliated with Medisyn Technologies, Inc. The authors also hold a patent: “Compositions for treatment of Alzheimers disease using abeta-reducing and/or abeta-anti-aggregation compounds”. Mount Sinai School of Medicine of New York University, USA, Inc Medisyn Technologies, editors. Patent Application Country: Application: WO; WO; Priority Application Country: US patent WO2010114636. 2010 1007; Patent Application Date: 20100405.; Priority Application Date: 20090403). There are no other patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","03","Jun Wang","JW",12,TRUE,4,8,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
